What were the two distinct approvals at the Gujarat Themis board meeting?

First, it signed off on routine FY26 financial results and a final dividend. Second, it approved a proposal for a preferential equity issue to non-promoter investors.

Why is the preferential issue notable if the terms are undecided?

It signals a planned capital infusion that will dilute existing shareholders. By approving the structure without the quantum or pricing, the board has committed to a raise whose cost is still unknown.

What is the next step for the preferential allotment?

The company must now secure shareholder and regulatory approvals. The specific details of the issue size, pricing, and investor will be determined later.

Pharmaceuticals · Small cap

Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.

FY26 results are routine. The board's separate approval for a preferential equity issue to non-promoters is not.

— 2 earlier stories on Gujarat Themis Biosyn Ltd. →

GUJTHEM By Tipsheet Editorial 25 May 2026 · 3:09 PM IST Verify on BSE · NSE

Mkt cap₹4,390 cr

P/E94.05×

ROE19.64%

Debt / eq.0.12

Div yld0.17%

₹168.5 cr / ₹46.7 cr FY26 revenue and net profit.

What's new

Board approved FY26 audited results: ₹168.5 cr revenue, ₹46.7 cr net profit.
Final dividend of ₹0.67 per share recommended.
Board cleared a preferential equity issue to non-promoters; quantum and pricing pending.

Why this matters

The financial results and dividend are standard compliance items. The preferential issue approval is a blank cheque for a capital raise and dilution. The board has greenlit the move without setting the terms, leaving the impact on existing shareholders undefined.

What we're watching

Identity of the non-promoter investor(s) and the size of the raise.
The discount, if any, to market price at which new shares will be issued.
Shareholder vote and regulatory timeline for the allotment.

The full read

Gujarat Themis Biosyn's FY26 results are straightforward: ₹168.5 crore in revenue, ₹46.7 crore in profit, a ₹0.67 dividend. None of that moves the needle. The separate board approval for a preferential issue to non-promoters does. It is a green light for a new equity raise, but one without a fixed price, a fixed size, or a named buyer. That creates a specific risk: the terms will be set later, and existing shareholders will have to live with them. The company now begins the process of seeking approvals for a deal whose central numbers are still blank.

Questions answered

What were the two distinct approvals at the Gujarat Themis board meeting?: First, it signed off on routine FY26 financial results and a final dividend. Second, it approved a proposal for a preferential equity issue to non-promoter investors.
Why is the preferential issue notable if the terms are undecided?: It signals a planned capital infusion that will dilute existing shareholders. By approving the structure without the quantum or pricing, the board has committed to a raise whose cost is still unknown.
What is the next step for the preferential allotment?: The company must now secure shareholder and regulatory approvals. The specific details of the issue size, pricing, and investor will be determined later.

Mentioned: Gujarat Themis Biosyn · Non-promoters (unspecified) · Final dividend ₹0.67

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on GUJTHEM →

25 May 2026 · 3:09 PM IST Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
today Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
12d ago Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm